Panpure

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Panpure

Property Description
Active Ingredient Pantoprazole (as sodium salt)
Pharmacological Class Proton Pump Inhibitor (PPI)
Common Form Enteric-Coated, Delayed-Release Tablet
Route of Administration Oral or Intravenous (as powder for injection)
Origin Synthetic Substituted Benzimidazole

What is Panpure and What Class Does It Belong To?

Panpure is a prescription-only medicinal preparation whose active ingredient is Pantoprazole (INN), a compound chemically identified as a synthetic substituted benzimidazole. The medication is classified as a Proton Pump Inhibitor (PPI), a pharmacological category clinically recognized for its potent ability to regulate gastric acidity. Panpure is typically available as a prescription-only medicine, differentiating its status from lower-strength, non-prescription acid reducers. The preparation is manufactured and marketed by Emcure Pharmaceuticals Ltd., and its specific formulation features a specialized enteric coating designed to optimize the drug’s delivery to the intended site of absorption.

Pantoprazole: Composition and Foundational Mechanism

The core composition of Panpure contains Pantoprazole (as the sodium salt), which is most commonly formulated into an enteric-coated, delayed-release tablet. This design is essential because the drug is highly sensitive to acid and must be protected until it reaches the small intestine for systemic absorption. Once absorbed, Pantoprazole acts by achieving the profound and sustained inhibition of gastric acid secretion. It achieves this by irreversibly binding to the H^+/K^+ ATPase enzyme system—the gastric proton pump—located in the parietal cells, thus blocking the final step of acid production.

What is the General Purpose of Panpure?

The general purpose of Panpure is to achieve a substantial and long-lasting reduction in the total amount of corrosive acid within the stomach and esophagus. This capability provides consistent relief from the irritation and discomfort caused by hyperacidity, such as the burning sensation often associated with acid reflux. By maintaining a significantly lowered level of acid, the drug creates a beneficial environment, enabling the body's affected internal linings to heal from acid-induced damage. The use of this drug is characteristic in scenarios where patients require sustained and pronounced acid suppression to facilitate recovery.

Regulatory References

  1. Pantoprazole Sodium Label (DailyMed)

What side effects are possible with Panpure?

Possible Side Effects and Safety Information

The safety profile of Panpure, containing pantoprazole, is established by official documentation from regulatory authorities, classifying adverse reactions by frequency and affected body system. The medicine’s use may be associated with side effects primarily concerning the Gastrointestinal System and Nervous System.


Official Frequency Classification

The most frequently occurring adverse reactions are classified as Common in regulatory documents (ge 1/100 to < 1/10), and include Headache, Diarrhea, Nausea, Abdominal pain, Vomiting, and Flatulence. Reactions classified as Uncommon include rash, pruritus (itching), dizziness, and sleep disorders. The official label also notes the risk of Bone fracture (hip, wrist, or spine) as Uncommon, particularly with long-term or high-dose therapy.


Serious Adverse Reactions and Duration-Related Safety

Several serious adverse reactions, often documented from post-marketing surveillance, are considered Rare or of Not Known frequency. These include Acute Tubulointerstitial Nephritis (ATIN), severe Hypersensitivity Reactions (Anaphylaxis), and severe skin reactions such as Stevens-Johnson Syndrome (SJS).

Regulatory documents highlight safety patterns linked to long-term use (generally ge 3 months or ge 1 year). This prolonged exposure is associated with an increased risk of developing Hypomagnesemia (low magnesium levels), Vitamin B-12 deficiency, and Fundic Gland Polyps.


Safety Considerations

The medicine is contraindicated in patients with a known hypersensitivity to pantoprazole or any substituted benzimidazole. Furthermore, official labeling requires that gastric malignancy be ruled out before initiating treatment, as a symptomatic response does not exclude its presence. Specific monitoring of liver enzymes is mandated for patients with severe hepatic impairment, as noted in the official prescribing information.

Overdose and Emergency Response

Overdose and when to seek help

The following information details the documented overdose profile for Panpure (pantoprazole) based exclusively on regulatory prescribing information and official health authority guidance.

Feature Official Regulatory Statement
Documented overdose presentations Overdose symptoms are generally within the known safety profile of the medication; experience with doses exceeding 240 mg is formally limited.
Emergency-response statements Contact the Poison Control Center for current information on the management of overdosage.
When immediate medical help is required Seek medical attention, particularly if clinical signs of intoxication manifest.

Overdose Management Profile

Classification Official Regulatory Statement
Antidote No specific antidote is known.
Management Protocol Treatment for overdosage should be symptomatic and supportive.
Procedural Constraint The drug is not removed by hemodialysis.

Official Overdose Statements:

  • Treatment for overdosage should be symptomatic and supportive.
  • Clinical experience with single doses exceeding 240 mg is formally documented as limited.
  • The drug is explicitly stated to be not removed by hemodialysis.
  • Individuals should contact the Poison Control Center for specialized guidance upon overexposure.

Connection to the overall overdose profile: The regulatory profile establishes that high-dose exposure experience is limited, and manifestations are generally restricted to the known safety profile. Since no specific antidote is known and standard clearance procedures like hemodialysis are ineffective, regulatory agencies mandate that treatment be symptomatic and supportive, requiring individuals to contact a Poison Control Center or seek medical attention upon clinical signs of intoxication.

Therapeutic Uses of Panpure

Quick Facts: Therapeutic Domains

  • Gastroesophageal Reflux Disease (GERD): Indicated for the management and healing of erosive esophagitis associated with GERD, and for the long-term maintenance of healing of this condition.
  • Pathological Hypersecretory Conditions: Used to address conditions involving excessive stomach acid production.
  • Zollinger-Ellison Syndrome (ZES): Utilized for the long-term management of ZES, a condition characterized by high acid secretion.

What Panpure Treats: Main Uses and Benefits

Panpure is a prescription medication utilized in a therapeutic capacity to address specific conditions related to gastric acid secretion. The primary approved uses focus on supporting the healing of tissue damage and managing discomfort resulting from excess acid production in the stomach.

Panpure is indicated for the short-term treatment of erosive esophagitis, a form of tissue damage in the esophagus associated with Gastroesophageal Reflux Disease (GERD). In patients who have achieved healing, the medication is also used for the maintenance of that healing to reduce the relapse rate of symptoms such as heartburn.

Additionally, this medicine is a component of the long-term management plan for pathological hypersecretory conditions, including a rare disorder known as Zollinger-Ellison Syndrome. These applications are established for the medication’s indications and use.

Eligibility and Restrictions for Use

The official eligibility profile for Panpure (Pantoprazole) is defined by stringent regulatory criteria that determine which populations may use the medicine and which are restricted or prohibited.

Contraindicated Populations

Use of Panpure is strictly prohibited in individuals with a known hypersensitivity to pantoprazole, related substituted benzimidazoles, or any component of the formulation. Additionally, the medicine is contraindicated for patients concurrently receiving medicinal products containing rilpivirine.

Age and Physiological Restrictions

Adults (18 years and older) are the primary eligible population. For pediatric patients, oral use is generally not recommended for those under 12 years of age, as safety and efficacy have not been established. Pregnant and lactating individuals are populations for whom use is generally not recommended by regulatory agencies due to insufficient human data.

Condition-Based Eligibility

Patients with severe hepatic impairment (severe liver disease) are subject to restricted use and monitoring. Use is generally allowed in patients with renal impairment, requiring no mandatory dose adjustment. Long-term use is restricted for populations at risk of osteoporosis-related fractures or hypomagnesemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile of Panpure (pantoprazole) is defined by its effect on gastric acidity and its role in hepatic metabolism, which lead to specific regulatory restrictions and warnings regarding co-administration with certain medicinal products.

Formal Contraindicated Combinations

Co-administration with Rilpivirine-containing products is formally prohibited. This restriction exists because the profound reduction in gastric acid secretion caused by pantoprazole results in a significant decrease in the plasma exposure of Rilpivirine, which compromises the antiviral's efficacy.

Pharmacokinetic and Exposure-Altering Interactions

Pantoprazole significantly elevates gastric pH, a condition that reduces the absorption and subsequent bioavailability of medicines that require an acidic environment. This includes several antifungal agents, such as Ketoconazole and Itraconazole, as well as certain tyrosine kinase inhibitors, including Dasatinib and Erlotinib. Similar effects apply to some HIV antivirals like Atazanavir and Nelfinavir, leading to warnings about reduced concentrations.

Pantoprazole is metabolized primarily by the hepatic enzyme CYP2C19 and acts as a weak inhibitor of this enzyme. Co-administration with Warfarin has been associated with an increase in the International Normalized Ratio (INR). Additionally, use with high-dose Methotrexate may elevate and prolong serum concentrations of methotrexate and its metabolite. Administration with food does not significantly affect the drug's overall absorption.

Mechanism of Action

Irreversible Inactivation of the Acid-Producing Enzyme

The mechanism of action centers on Pantoprazole functioning as an irreversible, non-competitive inhibitor of the H^+/K^+ ATPase enzyme system—the gastric proton pump—located in the parietal cells. The drug is activated by acid in the cell's secretory environment and then forms a stable, covalent bond with the pump, resulting in its inactivation and preventing the transport of hydrogen ions ( H^+) into the stomach lumen.


Inactivation of the Final Common Pathway of Secretion

By acting directly on the proton pump, the drug inactivates the final common pathway for all stimuli—including histamine, gastrin, and acetylcholine—that trigger acid release. This mechanistic approach results in a marked and sustained elevation of gastric pH (hypochlorhydria).


Mechanism-Driven Duration and Onset

The duration of the H^+ efflux cessation is determined by the biological half-life of the enzyme itself, not its plasma clearance. Since the binding is irreversible, the acid-suppressing effect persists until the parietal cell synthesizes and inserts new proton pumps. This mechanism explains the resulting long duration of H^+ efflux cessation (24+ hours) and the requirement for 3 to 5 days of progressive pump inhibition to achieve maximal pH elevation.

Dosage and Administration Information

Panpure, whose active ingredient is Pantoprazole, is utilized through specific administration protocols. The primary method involves oral intake using delayed-release tablets in 20 mg or 40 mg strengths. When oral administration is temporarily infeasible, the medication may be administered intravenously (IV) using the powder for injection form.

For the short-term treatment of erosive esophagitis, the standard adult regimen is 40 mg once daily. For long-term management of pathological hypersecretory conditions, dosing typically begins at 40 mg twice daily and may be adjusted. The tablets are required to be swallowed whole and must not be crushed, split, or chewed, a constraint necessary to preserve the protective enteric coating and ensure proper absorption.

Administration timing varies slightly by form; the oral tablets can be taken with or without food, while granules should be taken approximately 30 minutes before a meal. Procedural guidelines stipulate that the IV infusion should be administered over a period of about 15 minutes and is limited to a short duration, usually no more than 7 to 10 days. Protocols also include population-specific adjustments: for patients with severe hepatic impairment, the dose should not exceed 20 mg per day. If a dose is missed, it should be taken promptly, unless it is close to the time for the next scheduled dose, in which case the missed dose is omitted.

Recent Clinical Evidence

Research evidence / Overview of studies for Panpure

Evidence for Use in Healing Erosive Esophagitis

Research exploring the medicine as a subject of study in patients with erosive esophagitis (the tissue damage caused by severe acid reflux (GERD)) is primarily based on short-term, randomized controlled trials (RCTs). These studies were used in research exploring how symptoms change over time and evaluate patient-reported experiences over defined time intervals, usually lasting four to eight weeks. The outcomes monitored were often related to the physical discomfort associated with acid reflux, and researchers carefully measured the endoscopic healing rate.

Findings from these RCTs describe patterns observed in the studies related to both measurements of endoscopic healing and the reporting of symptoms. Separate trials were also conducted where Panpure was studied for use in specific age groups, including children and adolescents with endoscopically confirmed GERD, examining how symptoms and healing evolved in these younger populations.


Evidence for Long-Term Management

Once the initial acid-related tissue damage has been tracked, subsequent research explores the role of the medicine in preventing the recurrence, or relapse, of that damage and related symptoms. This evidence comes from controlled maintenance trials that typically tracked adult patients who achieved initial healing for an intermediate duration, often 6 to 12 months. These studies tracked the relapse rate, which measures the recurrence of acid-related symptoms and tissue damage (endoscopic evidence of erosion recurrence).

It is important to note that while these trials track patients for up to a year, controlled data specifically tracking maintenance measurements beyond 12 months are generally limited. Consequently, the sustained status of measured parameters and the need for continued long-term follow-up beyond this intermediate period are not fully established by the core controlled trials and often rely on longer, but less controlled, observational data.


Evidence for Pathological Hypersecretory Conditions

Research exploring the use of the medicine in rare conditions involving excessive stomach acid production, such as Zollinger-Ellison Syndrome (ZES), differs significantly from GERD trials. Due to the rarity of these conditions, the evidence base is composed primarily of long-term open-label studies and pharmacodynamic research, not large-scale RCTs. The key limitations here stem from the rarity of the condition: sample sizes were modest across studies, and the research predominantly utilizes an open-label design.

Key Studies & References

  1. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis (Escourrou J. et al.)
  2. The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid (NIH/ClinicalTrials.gov)

Frequently Asked Questions (FAQ)

Common questions about Panpure (FAQ)


Q: Are there any common foods to avoid when taking Panpure?

Official information indicates that taking the delayed-release tablet form with food does not significantly affect how the drug is absorbed. Regulatory sources do not mandate the avoidance of specific foods. Acidic foods and drinks are known to stimulate acid production, which is a consideration independent of the medicine's mechanism.


Q: Can you take Panpure on an empty stomach?

The delayed-release tablets can be taken either with or without food. In contrast, the oral granules have specific instructions, which require them to be administered approximately 30 minutes before a meal to align with official guidelines for that specific formulation.


Q: What happens if I miss a scheduled dose of Panpure?

According to official product information, if a dose is missed, it should be taken as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely, and the regular dosing schedule can be resumed.


Q: Does Panpure interact with common over-the-counter cold medicines?

The official label details significant interactions with certain prescription medicines, such as those that require an acidic stomach environment for effective absorption. While specific interactions with general over-the-counter cold medicines are not universally detailed, any co-administered medicine requiring an acidic stomach environment may be affected, potentially resulting in reduced absorption.


Q: Can Panpure interact with herbal products?

Authoritative sources advise that certain herbal products, such as St. John’s wort, may potentially interfere with the drug’s metabolism and could reduce its overall effectiveness. The potential for herbal products to affect how the body processes the medication is a key consideration when reviewing the drug's interaction profile.


Q: Is it safe to use during pregnancy (informational)?

Regulatory agencies generally indicate that the use of this medicine is not recommended during pregnancy. This is due to the limited and insufficient data from human studies concerning any potential risks associated with the medicine.


Q: Can Panpure be crushed or mixed into food?

The delayed-release tablets must be swallowed whole and should not be crushed, split, or chewed, as this damages the protective coating. Conversely, the delayed-release oral granules, a different formulation, may be mixed with certain substances like applesauce or apple juice for administration.


Q: How long does Panpure stay in your system?

The drug itself is rapidly processed by the body with a short elimination half-life of about one hour. However, because it binds irreversibly to the proton pumps, the acid-suppressing effect persists for 24 hours or longer until the body can synthesize and insert new proton pumps.


Q: What is the maximum duration Panpure has been studied for continuous use?

Controlled clinical studies used to establish the drug's role in the maintenance of healing typically monitored patients for an intermediate duration, usually up to 12 months. Official evidence notes that controlled data specifically tracking continuous use beyond this period are generally limited.


Q: Is Panpure a drug that requires regular monitoring?

Official labeling advises specific monitoring measures for certain patient groups. For instance, monitoring of liver enzymes is required for those with severe hepatic impairment, and checking magnesium levels is suggested for patients on long-term therapy, generally three months or longer.


Q: Is it true that Panpure needs to be taken at a specific time of day?

For consistency of effect, regulatory sources generally recommend that the prescribed dose is taken at approximately the same time each day. Specific timing rules apply to the different formulations: the tablets can be taken anytime, while the granules should be taken about 30 minutes before a meal.


Q: Can people with kidney problems use Panpure?

Official regulatory information indicates that for patients with renal impairment (kidney problems), no mandatory dose adjustment is required. This assessment is based on the known pharmacokinetic profile of the medicine.


Q: Is Panpure a type of antibiotic?

No. The medicine is officially classified as a Proton Pump Inhibitor (PPI), a pharmacological class designed specifically to reduce stomach acid production. It is not an antibiotic, though it may be used in combination with antibiotics to treat certain bacterial infections.


Q: Is Panpure known to cause weight gain?

Weight gain is not listed among the commonly reported adverse reactions in the official prescribing information derived from clinical trials. The product label primarily details adverse events that occurred with high frequency during the initial studies.


Q: Can Panpure be used for pain relief?

The FDA-approved uses are specific to conditions related to excessive stomach acid production, such as erosive esophagitis. It is not approved by regulatory bodies for use as a general pain reliever.


Q: Is Panpure considered a high-risk medication?

The medicine is generally described in official sources as well-tolerated. However, regulatory agencies require specific warnings regarding potential risks of long-term use, which include bone fracture, hypomagnesemia (low magnesium levels), and Vitamin B12 deficiency.


Q: Does Panpure make you drowsy or tired?

The official label lists dizziness as a Common adverse reaction and sleep disorders as Uncommon. General fatigue or tiredness has also been cited as a possible side effect, though official warnings highlight that tiredness may also be linked to duration-related safety concerns like low magnesium levels.


Q: What's the difference between Panpure and other similar medicines (non-clinical)?

The medicine is classified as a Proton Pump Inhibitor (PPI). This class of drugs works by irreversibly blocking the final step of acid production. This mechanism of action is distinct from other acid-reducing agents, such as H2 receptor blockers, which have a different target.


Q: How long do most people typically take Panpure for?

Treatment durations vary according to the condition being addressed. This can range from short-term treatment, such as 8 weeks for healing tissue damage caused by acid reflux, to long-term use required for maintenance therapy or for managing rare hypersecretory conditions.


Q: Is it safe to drink coffee while on Panpure?

No specific drug-coffee interaction is listed in the official label. However, regulatory information notes that acidic beverages, such as coffee, are known to stimulate the stomach to produce more acid. This effect might counteract the medicine's purpose or worsen acid-related symptoms for some individuals.


Q: Has Panpure been studied in older adults?

Yes, official clinical trials for the medicine included a sufficient number of geriatric subjects (aged 65 years and over). Official analyses determined that, overall, no differences in safety or effectiveness were observed when comparing older patients to younger adults.


Q: Do you need a special diet when using Panpure?

Official documents do not mandate a specific general diet to be followed while using this medicine. Although the tablets can be taken without regard to meals, official sources indicate that people may find it beneficial to limit foods or drinks known to trigger their individual acid reflux symptoms.


Q: Can Panpure affect sleep patterns?

Official documentation lists 'sleep disorders' as an Uncommon adverse reaction. Separately, dizziness is listed as a common reaction, which may also be relevant to sleep patterns and overall well-being.


Q: Are there any long-term effects of taking Panpure?

Prolonged use, typically defined as three months or longer, has been associated in regulatory warnings with specific long-term health concerns. These include the increased risk of developing hypomagnesemia (low magnesium levels), Vitamin B-12 deficiency, and bone fracture.


Q: Can Panpure cause hair loss?

Hair loss (alopecia) is not listed among the common or uncommon adverse reactions in official prescribing information based on initial clinical trials. However, it is occasionally cited in post-marketing reports as a rare event.


Q: Does Panpure change how other medicines work in the body?

Yes, it can. Because the drug causes a substantial reduction in stomach acid, it can decrease the absorption of other medicines that require an acidic environment to be effective. It may also affect the action of certain drugs that are processed by the liver's CYP2C19 enzyme.


Q: Why do some people say Panpure is hard on the stomach?

The official product documentation lists common gastrointestinal issues among the most frequently reported adverse reactions from clinical trials. These issues, which include diarrhea, nausea, abdominal pain, vomiting, and flatulence, may lead to the perception of the medicine causing stomach discomfort.


Q: Can Panpure cause anxiety or mood changes?

Official documents include psychiatric disorders, such as anxiety, depression, and hallucinations, as rare or very rare adverse reactions. These findings are primarily based on observations from post-marketing surveillance after the drug became widely available.


Q: What if I feel no effect after starting Panpure?

The maximal acid-suppressing effect of the medicine is typically not immediate. Because its mechanism requires cumulative inhibition of the proton pumps, official information indicates that it may take 3 to 5 days of continuous therapy to achieve the full, maximal effect.


Q: Is Panpure a treatment that cures a condition?

For the majority of acid-related conditions like erosive esophagitis, the medicine is indicated for the short-term healing of tissue damage and/or the long-term maintenance of that healing. Its use is consistent with managing a chronic condition rather than providing a permanent cure.


Q: Does Panpure have a risk of dependence or addiction?

The medicine is not classified as a controlled substance and is not associated with psychological dependence or addiction. However, discontinuing use of any Proton Pump Inhibitor may be associated with temporary rebound acid secretion, which can cause symptoms to return or temporarily worsen.


Q: Is Panpure a relatively new medicine or has it been around for a long time?

The active ingredient, Pantoprazole, is well-established. The initial formulation of the drug received its first major regulatory approval in the year 2000, meaning it has been available globally for several decades.

How should Panpure be stored and disposed of?

How to Store and Dispose of Panpure (Pantoprazole)

Official regulatory guidelines dictate specific conditions for storing Pantoprazole delayed-release tablets to ensure product stability.


Storage Requirements

Condition Regulatory Mandate
Temperature Store at Controlled Room Temperature (20 C to 25 C), with excursions permitted up to 30 C.
Protection Keep in the original container, tightly closed, and protected from moisture. Do not refrigerate or freeze.
Safety Keep the medication out of the sight and reach of children.

Disposal Instructions

Unused or expired Panpure must be disposed of according to local pharmaceutical waste regulations. Use an approved drug take-back program whenever available. The product must not be thrown away in wastewater (flushed down the toilet or poured down the sink).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Panpure found in:

A-Z Index: